Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Ecnoglutide

Ecnoglutide

GLP-1 (biased agonist) · s.c. · Sciwind

Data cut 12 November 2026 · page built 16 November 2026 · 8 trial arms · 5 trials with results · 7 registered trials · see on the pipeline board

Summary

Also known as
XW003
Mechanism
GLP-1 (biased agonist)
Route
s.c.
Company
Sciwind
Highest development stage
approved
Status (as of data cut)
Approved in China: T2D (January 2026) and weight management (March 2026); SLIMMER published (Lancet Diabetes Endocrinol 2025) verify
Next milestone
Global development (Verdiva/Pfizer licence for oral)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity4 approved / in labelNMPA (China), weight management, March 2026NMPA approval, Sciwind press release (Mar 2026); EECOH-1
T2D4 approved / in labelNMPA (China), January 2026NMPA approval, Sciwind press release (Jan 2026)
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA2 phase 3 ongoingPhase 3 ongoing
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
SLIMMER-UP-SWITCH (interim)2.4 mg vs semaglutide 2.4 mg: weight -9.5 %obesity china20163——−12.8 %
estimand not specified
———————press release
EECOH-10.6 mgt2d china24211——−4.5 % vs −2.0 %
estimand not specified
−2.0 vs −0.91.4 vs 1.44.3 vs 2.87.2 vs 9.9—2.9 vs 5.6—press release
EECOH-1 (T2D monotherapy)ecnoglutide 1.2 mgt2d china2471—−4.7 % vs −2.0 %
Δ −2.7 pp
−2.4 vs −0.91.4 vs 1.45.6 vs 2.812.7 vs 9.9—4.2 vs 5.6−5.2 vs −2.1verified
EECOH-20.6 mg vs dulaglutide 1.5 mg: HbA1c -1.65t2d china32623——−1.93.0—————press release
EECOH-21.2 mg vs dulaglutide 1.5 mg: HbA1c -1.65t2d china32623——−1.94.0—————press release
SLIMMER1.2 mgobesity china48664—−9.9 % vs −0.3 %
Δ −9.6 pp
———————press release
SLIMMER1.8 mgobesity china48664—−13.3 % vs −0.3 %
Δ −13.0 pp
———————press release
SLIMMER2.4 mgobesity china48664—−15.4 % vs −0.3 %
Δ −15.1 pp
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (21)
  • ecnoglutide 1.2 mg · weight_tp · Results, Secondary outcomes; Table 2
    −4.74% (−5.65 to −3.82) with 1.2 mg ecnoglutide
  • ecnoglutide 1.2 mg · ae_dc · Results, Safety outcomes; Table 3
    TEAEs led to premature treatment discontinuation in 1 (1.4%) participant in each treatment group (Table 3).
  • ecnoglutide 1.2 mg · disc_any · Results, Study participants (denominator 71 from Table 3/Fig
    including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group
  • ecnoglutide 1.2 mg · nausea · Table 3
    Nausea 9 (12.7) 5 (7.2) 7 (9.9)
  • ecnoglutide 1.2 mg · sae · Results, Safety outcomes; Table 3
    Serious TEAEs were reported in 2.9% (2/69) of the 0.6 mg ecnoglutide group, 4.2% (3/71) of the 1.2 mg ecnoglutide group, and 5.6% (4/71) of the placebo group.
  • ecnoglutide 1.2 mg · hba1c · Results, Primary outcome; Table 2
    −2.43% (−2.65 to −2.20) with 1.2 mg ecnoglutide
  • ecnoglutide 1.2 mg · sbp · Results, Safety outcomes
    a mean of 5.2 mmHg with 1.2 mg ecnoglutide
  • 1.2 mg · weight_tp · press release
    Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
  • 1.8 mg · weight_tp · press release
    Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
  • 2.4 mg · weight_tp · press release
    Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
  • 2.4 mg · weight_unsp · press release
    the least-squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide group
  • 0.6 mg · hba1c · press release
    HbA1c change from baseline | -0.87 % | -1.96% ( P =0.0003) | -2.43% ( P< 0.0001)
  • 0.6 mg · weight_unsp · press release
    Percent body weight change from baseline | -2.02 % | -4.51% ( P =0.0002) | -4.74% ( P< 0.0001)
  • 0.6 mg · ae_dc · press release
    A total of three subjects, one (1.4%) from each cohort, discontinued the study due to adverse events.
  • 0.6 mg · disc_any · Results, para 1
    and safety set, and 9 (4%) of them discontinued treatment prematurely in the double-blind period, including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group (r
  • 0.6 mg · nausea · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
    Nausea 9 (12.7) 5 (7.2) 7 (9.9)
  • 0.6 mg · sae · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
    Serious TEAEs 3 (4.2) 2 (2.9) 4 (5.6)
  • 0.6 mg · hba1c · publication (abstract)
    At week 32, mean HbA1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg
  • 0.6 mg · ae_dc · publication
    six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events
  • 1.2 mg · hba1c · publication
    1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide.
  • 1.2 mg · ae_dc · publication
    six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events

Registered trials (7)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
SLIMMER-YOUNG
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
ObesityPhase 3not yet recruiting2026-10 → 2028-06192not yet recruitingNCT07836270
KOA
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
Knee OAPhase 3recruiting2026-08 → 2028-05360recruitingNCT07734311
NCT07434050
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
Sleep apnoeaPhase 3recruiting2026-03 → 2028-06140recruitingNCT07434050
NCT07387094
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
Sleep apnoeaPhase 3recruiting2026-02 → 2027-12140recruitingNCT07387094
SLIMMER
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
ObesityPhase 3completed2023-04 → 2024-06664Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05813795
NCT05680129
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
T2DPhase 3completed2023-01 → 2024-07623Completed; results not in the atlas yetNCT05680129
NCT05680155
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
T2DPhase 3completed2022-12 → 2024-06211Completed; results not in the atlas yetNCT05680155

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Ecnoglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ecnoglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.